Clinical Trial

Moderna Analyst Day Highlights Pipeline Progress and Business Strategy Updates

Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026Expects to expand seasonal vaccine…

1 month ago

Moderna Analyst Day Highlights Pipeline Progress and Business Strategy Updates

Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026Expects to expand seasonal vaccine…

1 month ago

Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For

AUSTIN, Texas, Nov. 20, 2025 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: As late-stage biotech pipelines mature, fair-value remeasurements under U.S.…

1 month ago

Shattuck Labs to Participate in Upcoming December Investor Conferences

AUSTIN, TX and DURHAM, NC, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK),…

1 month ago

Nanox Announces Third Quarter of 2025 Financial Results and Provides Business Update

Management to host conference call and webcast Thursday, November 20, 2025, at 8:30 AM ET Company advances commercialization and is on…

1 month ago

FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

HOUSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued…

1 month ago

Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results

– Post-implantation analysis of ATEVs demonstrates progressive recellularization with host cells, transforming the ATEV into a multi-layered living tissue similar…

1 month ago

Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1

Evaxion’s AI-Immunology™ platform has discovered novel CMV antigens that significantly reduce viral infection in preclinical models EVX-V1 is a next-generation, multi-component…

1 month ago

Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

 —Nebokitug PSC Phase 3 Design Near Completion Following Positive FDA Feedback— —Regulatory Alignment Advances, with EMA Guidance Supporting a Single…

1 month ago

Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer’s Disease Conference

New lecanemab findings highlight the safety and potential benefits of subcutaneous administration for initiation dosing, the potential for additional long-term…

1 month ago